Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume 70, Issue 8, Pages 2261-2274Publisher
SPRINGER
DOI: 10.1007/s00262-021-02848-0
Keywords
Lung squamous cell carcinoma; Single-cell RNA sequencing; PD-L1-negative; Pembrolizumab; Immune cells
Categories
Funding
- Natural Science Foundation of Shanghai [19ZR1449700]
- Shanghai Chest Hospital-Collaborative Innovation Project [YJXT20190204]
Ask authors/readers for more resources
This study used single-cell sequencing to explore cellular and molecular characteristics in PD-L1-negative lung squamous cell carcinoma patients. The study identified specific cell types, proportions, differentially expressed genes, and significant pathways in NKG7+ T, NKG7+ NK, Naive T, and CD8+ T cells. These findings may provide potential predictive markers for Pembrolizumab responsiveness in PD-L1-negative patients.
High expression of PD-L1 predicts PD-1/PD-L1 inhibitor benefit, meanwhile a few PD-L1-negative patients still benefit from these drugs. In this study, we aimed to explore the underlying cellular and molecular characteristics via single-cell sequencing. Before and after treatment with Pembrolizumab, peripheral blood mononuclear cells (PBMCs) were isolated via Ficoll gradient. Thereafter, single-cell RNA sequencing was performed, and clinical significance was validated with The Cancer Genome Atlas (TCGA) cohort. All 3423 cells of 16 clusters were classified into eight cell types, including NKG7+ T, NKG7+ NK, Naive T, CDC1C+ dendritic cells, CD8+ T cells, B cells, macrophages and erythrocytes. Cell proportion, the clinical significance of differentially expressed genes and significant pathways of NKG7+ T, NKG7+ NK, Naive T and CD8+ T cells were analyzed. Ubiquitin-mediated proteolysis/cell cycle/natural killer cell-mediated cytotoxicity were identified as PD-1 blockage-responsive pathways in NKG7+ NK cells. Apoptosis/Th1 and Th2 cell differentiation were proposed as Pembrolizumab-affected pathways in NKT cells. In gene level, ID2, PIK3CD, UQCR10, MATK, MZB1, IL7R and TRGC2 showed a significant correlation with PD-1 expression after TCGA dataset validation, which could possess potential as predictive markers for patients with PD-L1-negative lung squamous cell carcinoma who can benefit from Pembrolizumab.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available